Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Cortesi

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 28, 2019
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Alice Lunghi, Enrico Cortesi, et al.
Critical Reviews in Oncology/Hematology|April 22, 2017
Follow-up program in head and neck cancerFrancesca De Felice, Marco de Vincentiis, Valentino Valentini, et al.
Frontiers in Immunology|November 21, 2022
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapyAndrea Botticelli, Giulia Pomati, Alessio Cirillo, et al.
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 30, 2018
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access programMarina Chiara Garassino, Lucio Crinò, Annamaria Catino, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Oncotarget|March 1, 2018
<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancerChiara Cremolini, Marzia Del Re, Carlotta Antoniotti, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Future Oncology (London, England)|January 29, 2021
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patientsOrazio Caffo, Viviana Frantellizzi, Fabio Monari, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|December 28, 2019
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Alice Lunghi, Enrico Cortesi, et al.
Critical Reviews in Oncology/Hematology|April 22, 2017
Follow-up program in head and neck cancerFrancesca De Felice, Marco de Vincentiis, Valentino Valentini, et al.
Frontiers in Immunology|November 21, 2022
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapyAndrea Botticelli, Giulia Pomati, Alessio Cirillo, et al.
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 30, 2018
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access programMarina Chiara Garassino, Lucio Crinò, Annamaria Catino, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Oncotarget|March 1, 2018
<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancerChiara Cremolini, Marzia Del Re, Carlotta Antoniotti, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Future Oncology (London, England)|January 29, 2021
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patientsOrazio Caffo, Viviana Frantellizzi, Fabio Monari, et al.
Pageof 18